Volume 11 Issue 5
Sep.  2020
Turn off MathJax
Article Contents
Dong LIU, Chang-zhen ZHU, Wei-ming KANG. Research Progress of ETV1 and FOXF1 in Gastrointestinal Stromal Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 592-595. doi: 10.3969/j.issn.1674-9081.2020.05.015
Citation: Dong LIU, Chang-zhen ZHU, Wei-ming KANG. Research Progress of ETV1 and FOXF1 in Gastrointestinal Stromal Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 592-595. doi: 10.3969/j.issn.1674-9081.2020.05.015

Research Progress of ETV1 and FOXF1 in Gastrointestinal Stromal Tumors

doi: 10.3969/j.issn.1674-9081.2020.05.015
More Information
  • Corresponding author: KANG Wei-ming  Tel: 86-10-69152215, E-mail:kangweiming@163.com
  • Received Date: 2018-05-21
  • Publish Date: 2020-09-30
  • Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. They originate from interstitial cells of Cajal (ICC) or their homologous stem cells. Most of them are related to mutations in KIT or PDGFRA genes. The incidence, drug resistance rate of targeted therapy, and recurrence rate are increasing year by year, which greatly affect the prognosis of patients. The treatment of GISTs is facing bottlenecks, and searching for new treatment methods has become a current research hotspot of GISTs. ETV1 is a member of the transcription factors of ETS family, which can stimulate the transcription of KIT gene. KIT proteins enhance the expression of ETV1 through MEK-MAPK signaling pathway. The synergistic regulation of ETV1 and KIT positive feedback leads to continuous activation of intracellular signaling pathways in ICC/GISTs, thus promoting the proliferation of tumors. FOXF1 is highly expressed in GISTs, which may be an upstream regulator of KIT and ETV1 and promotes the expression of genes specific to ICC/GISTs. FOXF1 and ETV1 may provide new ideas and directions for the treatment of GISTs. This article reviews the relationship between ETV1, FOXF1 gene expression, and GISTs.
  • loading
  • [1] 崔宁宜, 王勇, 吕珂.小肠淋巴瘤和小肠间质瘤的超声征象及鉴别诊断[J].协和医学杂志, 2016, 7:342-346. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201605006
    [2] Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach[J]. Human Pathology, 2002, 33:459-465. doi:  10.1053/hupa.2002.123545
    [3] Dematteo RP, Ballman KV, Antonescu CR, et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2009, 373:1097-1104. doi:  10.1016/S0140-6736(09)60500-6
    [4] Miettinen M, Monihan JM, Sarlomorikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases[J]. Am J Surg Pathol, 1999, 23:1109-1118. doi:  10.1097/00000478-199909000-00015
    [5] Sarlomorikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34[J]. Mod Pathol, 1998, 11:728-734. https://pubmed.ncbi.nlm.nih.gov/9720500/
    [6] 邓志勇, 李海, 张阳, 等.胃肠道间质瘤误诊12例临床病理特征分析[J].中国误诊学杂志, 2006, 6:2547-2548. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgwzxzz200613084
    [7] Zhu CZ, Liu D, Kang WM, et al. Ghrelin and gas-trointestinal stromal tumors[J]. World J Gastroentero, 2017, 23:1758-1763. doi:  10.3748/wjg.v23.i10.1758
    [8] Heinrich MC. PDGFRA activating mutations in gastmintest-inal stromal tumor[J]. Science, 2003, 299:708-710. doi:  10.1126/science.1079666
    [9] Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up[J]. Am J Surg Pathol, 2005, 29:1373-1381. doi:  10.1097/01.pas.0000172190.79552.8b
    [10] Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopatho-logic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up[J]. Am J Surg Pathol, 2006, 30:477-489. doi:  10.1097/00000478-200604000-00008
    [11] Vadakara J, von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies[J]. Hematol Oncol Clin North Am, 2013, 27:905-920. doi:  10.1016/j.hoc.2013.07.007
    [12] Gramza AW, Corless CL, Heinrich MC. Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors[J]. Clin Cancer Res, 2009, 15:7510-7518. doi:  10.1158/1078-0432.CCR-09-0190
    [13] Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial[J]. Lancet, 2006, 368: 1329-1338. doi:  10.1016/S0140-6736(06)69446-4
    [14] Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science, 1998, 279: 577-580. doi:  10.1126/science.279.5350.577
    [15] Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors[J]. Gastroenterology, 2003, 125: 660-667. doi:  10.1016/S0016-5085(03)01046-1
    [16] Kurpios NA, Macneil L, Shepherd TG, et al. The Pea3 Ets transcription factor regulates differentiation of multipotent progenitor cells during mammary gland development[J]. Dev Biol, 2009, 325:106-121. doi:  10.1016/j.ydbio.2008.09.033
    [17] De LY, Baert JL, Chotteaulelievre A, et al. The Ets transcription factors of the PEA3 group: transcriptional regu-lators in metastasis[J]. BBA Rev Cancer, 2006, 1766:79-87.
    [18] Ordóñez JL, Osuna D, Herrero D, et al. Advances in Ewing's sarcoma research: Where are we now and what lies ahead?[J]. Cancer Res, 2009, 69:7140-7150. doi:  10.1158/0008-5472.CAN-08-4041
    [19] Jane-Valbuena J, Widlund HR, Perner S, et al. An Oncogenic Role for ETV1 in Melanoma[J]. Cancer Res, 2010, 70:2075-2084. doi:  10.1158/0008-5472.CAN-09-3092
    [20] Baker R, Kent CV, Silbermann RA, et al. Pea3 transcrip-tion factors and wnt1-induced mouse mammary neoplasia[J]. PLoS One, 2010, 5:e8854. doi:  10.1371/journal.pone.0008854
    [21] Vageli D, Ioannou MG, Koukoulis GK. Transcriptional activation of hTERT in breast carcinomas by the Her2-ER81-related pathway[J]. Oncol Res, 2009, 17:413-423. doi:  10.3727/096504009788912507
    [22] Oh S, Shin S, Janknecht R. ETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors[J]. Biochimica et Biophysica Acta, 2012, 1826:1-12.
    [23] Jané-Valbuena J, Widlund HR, Perner S, et al. An Oncogenic Role for ETV1 in Melanoma[J]. Cancer Res, 2010, 70:2075-2084. doi:  10.1158/0008-5472.CAN-09-3092
    [24] Dwyer J, He LI, Dakang XU, et al. Transcriptional Regulation of Telomerase Activity[J]. Ann NY Acad Sci, 2010, 1114:36-47.
    [25] Goueli BS, Janknecht R. Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf[J]. Mol Cell Biol, 2004, 24:25-35. doi:  10.1128/MCB.24.1.25-35.2004
    [26] Ran L, Sirota I, Cao Z, et al. Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth[J]. Cancer Discov, 2015, 5:304-315. doi:  10.1158/2159-8290.CD-14-0985
    [27] Chi P, Chen Y, Zhang L, et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours[J]. Nature, 2010, 467:849-853. doi:  10.1038/nature09409
    [28] 殷舞, 农涛, 黄顺荣, 等.胃肠间质瘤中ETV1的表达及意义[J].广东医学, 2017, 38:1358-1362. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gdyx201709014
    [29] Golson ML, Kaestner KH. Fox transcription factors: From development to disease[J]. Development, 2016, 143:4558-4570. doi:  10.1242/dev.112672
    [30] Lam EWF, Brosens JJ, Gomes AR, et al. Forkhead box proteins: tuning forks for transcriptional harmony[J]. Nat Rev Cancer, 2013, 13:482-495. doi:  10.1038/nrc3539
    [31] Wei HJ, Lo WC, Nickoloff JA, et al. FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells[J]. Oncotarget, 2014, 5:9514-9529. doi:  10.18632/oncotarget.2413
    [32] Ran L, Chen Y, Sher J, et al. FOXF1 defines the core-regulatory circuitry in gastrointestinal stromal tumor (GIST)[J]. Cancer Discov, 2018, 8:234-251. doi:  10.1158/2159-8290.CD-17-0468
    [33] Szafranski P, Dharmadhikari AV, Wambach JA, et al. Two deletions overlapping a distant/r, FOXF1/r, enhancer unravel the role of lncRNA/r, LINC01081/r, in etiology of alveolar capillary dysplasia with misalignment of pulmonary veins[J]. Am J Med Genet A, 2014, 164:2013-2019. doi:  10.1002/ajmg.a.36606
    [34] Tang CM, Lee TE, Syed SA, et al. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression[J]. Oncotarget, 2016, 7:78226-78241. doi:  10.18632/oncotarget.12909
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (361) PDF downloads(46) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return